NYSE: HAE - Haemonetics Corporation

Yield per half year: -13.68%
Dividend yield: 0.00%
Sector: Healthcare

Company Analysis Haemonetics Corporation

Download the report: word Word pdf PDF

1. Summary

Advantages

  • The stock's return over the last year (-13.96%) is higher than the sector average (-18.38%).
  • The company's current efficiency (ROE=13.22%) is higher than the sector average (ROE=-82.41%)

Disadvantages

  • Price (65.68 $) is higher than fair price (28.81 $)
  • Dividends (0%) are below the sector average (1.31%).
  • Current debt level 36.79% has increased over 5 years from 27.57%.

Similar companies

PFIZER

PerkinElmer

Humana

CVS Health Corporation

2. Share price and performance

2.1. Share price

2.2. News

No news yet

2.3. Market efficiency

Haemonetics Corporation Healthcare Index
7 days -2.3% -13.3% 2.7%
90 days -20.2% -13% -4.5%
1 year -14% -18.4% 10%

HAE vs Sector: Haemonetics Corporation has outperformed the "Healthcare" sector by 4.42% over the past year.

HAE vs Market: Haemonetics Corporation has significantly underperformed the market by -24.01% over the past year.

Stable price: HAE is not significantly more volatile than the rest of the market on "New York Stock Exchange" over the last 3 months, with typical variations of +/- 5% per week.

Long period: HAE with weekly volatility of -0.2685% over the past year.

3. Summary of the report

3.1. General

P/E: 35.77
P/S: 3.21

3.2. Revenue

EPS 2.29
ROE 13.22%
ROA 5.69%
ROIC 3.62%
Ebitda margin 20.29%

4. Fundamental Analysis

4.1. Stock price and price forecast

The fair price is calculated taking into account the Central Bank refinancing rate and earnings per share (EPS)

Above fair price: The current price (65.68 $) is higher than the fair price (28.81 $).

Price is higher than fair: The current price (65.68 $) is 56.1% higher than the fair price.

4.2. P/E

P/E vs Sector: The company's P/E (35.77) is lower than that of the sector as a whole (114.26).

P/E vs Market: The company's P/E (35.77) is lower than that of the market as a whole (73.05).

4.2.1 P/E Similar companies

4.3. P/BV

P/BV vs Sector: The company's P/BV (4.38) is lower than that of the sector as a whole (9.02).

P/BV vs Market: The company's P/BV (4.38) is lower than that of the market as a whole (22.32).

4.3.1 P/BV Similar companies

4.4. P/S

P/S vs Sector: The company's P/S indicator (3.21) is lower than that of the sector as a whole (4.1).

P/S vs Market: The company's P/S indicator (3.21) is lower than that of the market as a whole (15.91).

4.4.1 P/S Similar companies

4.5. EV/Ebitda

EV/Ebitda vs Sector: The company's EV/Ebitda (18.2) is higher than that of the sector as a whole (17.72).

EV/Ebitda vs Market: The company's EV/Ebitda (18.2) is lower than that of the market as a whole (23.05).

5. Profitability

5.1. Profitability and revenue

5.2. Earnings per share - EPS

5.3. Past profitability Net Income

Yield Trend: Rising and has grown by 10.73% over the last 5 years.

Earnings Slowdown: The last year's return (0%) is below the 5-year average return (10.73%).

Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-50.52%).

5.4. ROE

ROE vs Sector: The company's ROE (13.22%) is higher than that of the sector as a whole (-82.41%).

ROE vs Market: The company's ROE (13.22%) is lower than that of the market as a whole (25.12%).

5.5. ROA

ROA vs Sector: The company's ROA (5.69%) is lower than that of the sector as a whole (6.75%).

ROA vs Market: The company's ROA (5.69%) is lower than that of the market as a whole (6.65%).

5.6. ROIC

ROIC vs Sector: The company's ROIC (3.62%) is lower than that of the sector as a whole (15.68%).

ROIC vs Market: The company's ROIC (3.62%) is lower than that of the market as a whole (9.31%).

6. Finance

6.1. Assets and debt

Debt level: (36.79%) is quite low in relation to assets.

Increasing debt: over 5 years, the debt has increased from 27.57% to 36.79%.

Excess of debt: The debt is not covered by net income, percentage 687.14%.

6.2. Profit growth and share price

7. Dividends

7.1. Dividend yield vs Market

Low yield: The dividend yield of the company 0% is below the average for the sector '1.31%.

7.2. Stability and increase in payments

Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.

Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.

7.3. Payout percentage

Dividend Coverage: Current payments from income (6.08%) are at an uncomfortable level.

8. Insider trades

8.1. Insider trading

Insider Buying Exceeds insider sales by 100% over the last 3 months.

8.2. Latest transactions

Transaction date Insider Type Price Volume Quantity
12.07.2024 Lingamneni Anila
EVP, Chief Technology Officer
Sale 90 7 110 79
11.07.2024 Lingamneni Anila
EVP, Chief Technology Officer
Sale 90 192 240 2 136

Pay for your subscription

More functionality and data for company and portfolio analysis is available by subscription

9. Stocks forum Haemonetics Corporation

9.3. Comments